Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Relapse represents the main cause of treatment failure after stem cell transplantation (SCT). Thus, monitoring of minimal residual disease (MRD) in allografted patients allows an early detection of recurrence and a subsequent intervention prior to clinically detectable relapse. MRD assessment by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with chronic myeloid leukemia after allo-SCT. It is also recognized that it is a useful prognostic tool in several mature lymphoid and plasma cell disorders such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing and will define whether sensitive MRD detection allows for earlier therapeutic intervention to improve the outcome of SCT. We here discuss the methods of MRD evaluation in lymphoid and plasma cell disorders following transplantation with the ultimate aim of providing critical information for the setup of molecular approaches to detect MRD.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages209-237
Number of pages29
Volume1109
ISBN (Print)9781461494362
DOIs
Publication statusPublished - 2014

Publication series

NameMethods in Molecular Biology
Volume1109
ISSN (Print)10643745

Fingerprint

Residual Neoplasm
Plasma Cells
Transplantation
Lymphocytes
Stem Cell Transplantation
Recurrence
Mantle-Cell Lymphoma
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Multiple Myeloma
Decision Making
Clinical Trials
Polymerase Chain Reaction

Keywords

  • Lymphoid malignancies
  • Minimal residual disease
  • Multiple myeloma
  • Polymerase chain reaction
  • Stem cell transplantation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Corradini, P., & Carniti, C. (2014). Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. In Methods in Molecular Biology (Vol. 1109, pp. 209-237). (Methods in Molecular Biology; Vol. 1109). Humana Press Inc.. https://doi.org/10.1007/978-1-4614-9437-9_12

Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. / Corradini, Paolo; Carniti, Cristiana.

Methods in Molecular Biology. Vol. 1109 Humana Press Inc., 2014. p. 209-237 (Methods in Molecular Biology; Vol. 1109).

Research output: Chapter in Book/Report/Conference proceedingChapter

Corradini, Paolo ; Carniti, Cristiana. / Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders. Methods in Molecular Biology. Vol. 1109 Humana Press Inc., 2014. pp. 209-237 (Methods in Molecular Biology).
@inbook{c9df4462c4f64bf0bb77f166e7c2fa51,
title = "Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders",
abstract = "Relapse represents the main cause of treatment failure after stem cell transplantation (SCT). Thus, monitoring of minimal residual disease (MRD) in allografted patients allows an early detection of recurrence and a subsequent intervention prior to clinically detectable relapse. MRD assessment by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with chronic myeloid leukemia after allo-SCT. It is also recognized that it is a useful prognostic tool in several mature lymphoid and plasma cell disorders such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing and will define whether sensitive MRD detection allows for earlier therapeutic intervention to improve the outcome of SCT. We here discuss the methods of MRD evaluation in lymphoid and plasma cell disorders following transplantation with the ultimate aim of providing critical information for the setup of molecular approaches to detect MRD.",
keywords = "Lymphoid malignancies, Minimal residual disease, Multiple myeloma, Polymerase chain reaction, Stem cell transplantation",
author = "Paolo Corradini and Cristiana Carniti",
year = "2014",
doi = "10.1007/978-1-4614-9437-9_12",
language = "English",
isbn = "9781461494362",
volume = "1109",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "209--237",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders

AU - Corradini, Paolo

AU - Carniti, Cristiana

PY - 2014

Y1 - 2014

N2 - Relapse represents the main cause of treatment failure after stem cell transplantation (SCT). Thus, monitoring of minimal residual disease (MRD) in allografted patients allows an early detection of recurrence and a subsequent intervention prior to clinically detectable relapse. MRD assessment by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with chronic myeloid leukemia after allo-SCT. It is also recognized that it is a useful prognostic tool in several mature lymphoid and plasma cell disorders such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing and will define whether sensitive MRD detection allows for earlier therapeutic intervention to improve the outcome of SCT. We here discuss the methods of MRD evaluation in lymphoid and plasma cell disorders following transplantation with the ultimate aim of providing critical information for the setup of molecular approaches to detect MRD.

AB - Relapse represents the main cause of treatment failure after stem cell transplantation (SCT). Thus, monitoring of minimal residual disease (MRD) in allografted patients allows an early detection of recurrence and a subsequent intervention prior to clinically detectable relapse. MRD assessment by polymerase chain reaction-based methods is currently part of the routine clinical management of patients with chronic myeloid leukemia after allo-SCT. It is also recognized that it is a useful prognostic tool in several mature lymphoid and plasma cell disorders such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and multiple myeloma. In some of these entities, clinical trials employing MRD as a decision-making tool are currently ongoing and will define whether sensitive MRD detection allows for earlier therapeutic intervention to improve the outcome of SCT. We here discuss the methods of MRD evaluation in lymphoid and plasma cell disorders following transplantation with the ultimate aim of providing critical information for the setup of molecular approaches to detect MRD.

KW - Lymphoid malignancies

KW - Minimal residual disease

KW - Multiple myeloma

KW - Polymerase chain reaction

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84934437414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934437414&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-9437-9_12

DO - 10.1007/978-1-4614-9437-9_12

M3 - Chapter

SN - 9781461494362

VL - 1109

T3 - Methods in Molecular Biology

SP - 209

EP - 237

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -